Concerned about increasing its social responsibility, France Sanofi created a non-profit unit that will increase access to essential medicines to some of the world’s poorest countries. In an open letter to the company, CEO Paul Hudson outlined several key projects the company will implement to increase the impact of its corporate social responsibility (CSR) strategy.
The company’s strategy is based on four pillars on which Sanofi believes it is positioned to make a difference. These pillars are access to medicines, support to vulnerable communities, preservation of the environment and the inclusion and diversity of its employees. Access to medicines is a cornerstone of the company’s strategy. The Sanofi association aims to increase access to medicines considered essential by the World Health Organization in 40 low-income countries. Among these drugs, 30 produced by Sanofi are used in many therapeutic fields, in particular cardiovascular diseases, diabetes, tuberculosis, malaria and cancer. Sanofi will also fund the training of healthcare professionals or the development of sustainable care systems for those suffering from chronic diseases and requiring complex care, the company said.
In addition, Sanofi said it is committed to helping 1,000 rare disease patients who do not have access to treatment. The company will donate 100,000 vials of drugs for their treatments each year.
“The pandemic has forced us to question almost every aspect of our life: how we live and work, and how we connect with our communities and the planet. Yet as difficult as 2020 is, it has also brought us – Sanofi and the pharmaceutical industry – closer to our goal than at any time in living memory, ”Hudson said in a statement. “This unique context has led us to elevate our ambition for our corporate social responsibility strategy and to integrate it even more into our mission to transform lives and our vision for a better future.
In December, Sanofi renewed its five-year partnership with the WHO to fight neglected tropical diseases that affect around one billion people.
Elsewhere in the world:
Métrion Biosciences: UK-based Metrion Biosciences has secured £ 2.7million in new equity funding, including £ 2.25million from lead investor Gresham House Ventures. The funds from the funding round will be used to expand Metrion’s laboratories, invest in specialized equipment, expand its cell line library and add BPL cardiac safety services. The funding will also allow Metrion to expand its business development activities.
Genomics plc – Also UK based, Genomics plc. announced that a study showing that its new integrated risk tool can more accurately predict CVD risk across multiple ancestries and ethnicities has been published in The American Journal of Cardiology. In the article titled “Validation of an Integrated Risk Tool, Including Polygenic Risk Score, for Atherosclerotic Cardiovascular Diseases in Multiple Ethnicities and Ancestry”, researchers from Genomics plc and Stanford University authenticated the ‘clinical use of the company’s integrated risk tool, which also includes insight, showing that it outperforms existing standard care risk calculators currently in use in the US and UK
Avacta – Avacta Group plc and ABCAM plc have entered into a worldwide distribution agreement for the Company’s recently developed Affimer SARS-CoV-2 ELISA Research Reagents. Affirm from Avacta® The reagents can be used in a high performance ELISA laboratory assay to detect SARS-CoV-2 spike protein with high sensitivity and specificity for the spike protein of the original strain of the virus, as well as other dominant variants. Under the non-exclusive agreement, ABCAM will include Avacta’s SARS-CoV-2 spike protein Affimer research reagents in its online catalog.
Ecological – Another UK biopharmaceutical company, Mologic, has announced that its COVID-19 rapid antigen self-test has been selected by the US National Institutes of Health for RADx initiative funding. The Mologic Nasal Swab Test is designed for home use by non-healthcare professionals. The test indicates the presence of the SARS-CoV-2 nucleoprotein in about 20 minutes. The self-test can be used by anyone without medical training at the point of need, including at home, at work, at school, and while traveling. Mologic’s test moves to phase II testing. Mologic also makes this unique autotest design available to its customers and partners in a wide range of autotest applications, through the company’s contract research and manufacturing program.
RDIF – The Russian direct investment fund has reached an agreement with the Indian Panacea Biotech to produce 100 million doses of Sputnik V per year. Sputnik V is Russia’s COVID-19 vaccine. The partnership will be used to support the manufacture of the drug for Russian customers. Sputnik V has been registered in over 59 countries to date. The efficacy of Sputnik V is 91.6%, one of the three authorized vaccines which has an efficacy of over 90%. Sputnik V uses two different vectors as part of its two-dose regimen.
Delta 4 – Austrian firm Delta 4 closed a multi-million dollar Series A funding round. The company did not disclose the full increase, but said the funding would be used to accelerate its business development programs. Funding was provided by what has been described as “a large European Family Office investing in life sciences, technology and other industries”. In 2020, the company identified promising drug compounds for use in the treatment of rare kidney disease and COVID-19. Recently, these compounds have been prepared for phase II clinical studies. Delta 4 will now expand its clinical reach and launch discovery and development programs in other indications, the company said.